Structure via PubChem · Public domain (PubChem)
futibatinib
Sign in to saveAlso known as 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer). It is a kinase inhibitor. It is taken by mouth.
Chemical data
- Formula
- C22H22N6O3
- Molecular weight
- 418.4 g/mol
- IUPAC name
- 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one
- SMILES
- COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)[C@H]4CCN(C4)C(=O)C=C)OC
- InChIKey
- KEIPNCCJPRMIAX-HNNXBMFYSA-N
- XLogP
- 2
- Polar surface area
- 108 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2022
- Admin. routes
- oral
- Indications
- cholangiocarcinoma, soft tissue sarcoma, neoplasm, hepatocellular carcinoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 418.17533856399996
- Has use
- medication
Show 4 more facts
- isomeric SMILES
- COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)[C@H]4CCN(C4)C(=O)C=C)OC
- chemical formula
- C₂₂H₂₂N₆O₃
- canonical SMILES
- COc1cc(cc(c1)OC)C#Cc2c3c(ncnc3n(n2)C4CCN(C4)C(=O)C=C)N
- subject has role
- protein kinase inhibitors
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Society and culture
- Legal status
- Names
- References
Futibatinib, sold under the brand name Lytgobi, is an anti-cancer medication used for the treatment of cholangiocarcinoma (bile duct cancer). It is a kinase inhibitor. It is taken by mouth.
Futibatinib was approved for medical use in the United States in September 2022, in Japan in June 2023 and in the European Union in July 2023.
Excerpted from Wikipedia’s “futibatinib” article, available under the CC BY-SA 4.0 licence.